Syndax Pharmaceuticals, Inc.
SNDX
$10.99
$0.292.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 20.37% | 81.57% | 39.96% | -- |
| Gross Profit | -- | -6.44% | -49.59% | -29.89% | -- |
| SG&A Expenses | 78.23% | 65.46% | 80.14% | 94.86% | 92.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.23% | 33.55% | 81.13% | 56.44% | 72.80% |
| Operating Income | -5.03% | -23.70% | -58.95% | -49.39% | -72.80% |
| Income Before Tax | -17.19% | -29.94% | -64.48% | -52.56% | -76.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.19% | -29.94% | -64.48% | -52.56% | -76.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.19% | -29.94% | -64.48% | -52.56% | -76.04% |
| EBIT | -5.03% | -23.70% | -58.95% | -49.39% | -72.80% |
| EBITDA | -5.03% | -23.70% | -58.96% | -49.40% | -72.80% |
| EPS Basic | -15.89% | -9.85% | -34.49% | -24.58% | -43.44% |
| Normalized Basic EPS | -15.89% | -9.83% | -34.48% | -24.60% | -43.44% |
| EPS Diluted | -15.84% | -9.32% | -34.49% | -24.58% | -43.51% |
| Normalized Diluted EPS | -15.89% | -9.83% | -34.48% | -24.60% | -43.44% |
| Average Basic Shares Outstanding | 1.13% | 18.30% | 22.30% | 22.45% | 22.72% |
| Average Diluted Shares Outstanding | 1.13% | 18.30% | 22.30% | 22.45% | 22.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |